InflaRx N.V. (IFRX) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of InflaRx N.V. stock $0.51, price $1.18, that is 56.8% below the price, quality 25 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
InflaRx N.V.
IFRX · USFar too expensive (fair value 57% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $0.7305 – $6.10 · fair‑value band $0.3800 – $0.6400 · the $1.18 price screens above the $0.5100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether InflaRx is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Show moreShow less
Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications.
It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017.
The company was founded in 2007 and is headquartered in Jena, Germany.
Stock analysis
InflaRx N.V. (IFRX) currently trades at $1.18, while our estimate is $0.5100, 57% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.3800 (bear) to $0.6400 (bull), the price of $1.18 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
InflaRx N.V. reported revenue of €29.3K in FY2025 versus €0 in FY2021. Reported net income was −€45.6M in FY2025.
Key figures
Market cap $182M Micro · EPS (TTM) $−0.3700 · Return on equity −38.5% · Return on assets (EBIT) −52.7% (5-year average) · Operating margin 352,965% · Revenue (TTM) −$10.1K · Revenue growth (YoY) −80.8% · Free cash flow −€34.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 57% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −57%, IFRX screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare InflaRx N.V. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs IFRX |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs IFRX |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs IFRX |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs IFRX |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs IFRX |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs IFRX |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs IFRX |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs IFRX |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs IFRX |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs IFRX |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is InflaRx N.V. (IFRX) overvalued or undervalued?
What is the fair value of IFRX?
What is the quality score of IFRX?
What is the price target for InflaRx N.V. (IFRX)?
What is the InflaRx N.V. stock forecast for 2026?
What is the intrinsic value of InflaRx N.V. (IFRX)?
Is InflaRx N.V. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of IFRX?
How much is InflaRx N.V. worth?
What do the bullish and bearish scenarios say about IFRX?
How solid is the balance sheet of InflaRx N.V. (IFRX)?
How far is IFRX from its 52-week high?
Which stocks are comparable to InflaRx N.V.?
Is InflaRx N.V. stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of InflaRx N.V. (IFRX)?
What should I pay attention to with InflaRx N.V. right now?
Key figures of InflaRx N.V.
How large is the market capitalisation of InflaRx N.V. (IFRX)?
What are the earnings per share of InflaRx N.V. (IFRX)?
What is the return on equity of InflaRx N.V. (IFRX)?
What is the EBIT return on assets of InflaRx N.V. (IFRX)?
What is the operating margin of InflaRx N.V. (IFRX)?
How much revenue does InflaRx N.V. (IFRX) generate?
How fast is revenue growing at InflaRx N.V. (IFRX)?
How much free cash flow does InflaRx N.V. (IFRX) generate?
How much net cash does InflaRx N.V. (IFRX) hold?
Watch InflaRx N.V. in the live analysis
One click puts InflaRx N.V. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.